

September 10, 2019

Dear Provider:

Diabetic medication reminders, modifications effective October 1, 2019.

As one may be aware, costs of insulin have been rising and continue to do so. Currently there are two manufacturers making insulin lispro. Admelog will be the preferred manufacturer of the two brands. As both Admelog and Humalog are the same product clinically, the most cost effective manufacturer will be formulary. The two branded drugs are not allowed to substitute without an approval from the provider in accordance to FDA rules. It would be helpful for prescriptions to be written for insulin lispro and then pharmacies may select any manufacturer. As of **October 1, 2019**, only Admelog will be authorized.

Adlyxin: Added with Step Therapy. Allowed after 90 days of SGLT-2 therapy. Lowest cost GLP-1 and a component of Soliqua.

Trulicity: Endocrinologist requirement removed, will now process after 90 days of SGLT-2 therapy.

Ozempic: Allowed for endocrinologists.

Soliqua: Step Therapy. Requires prior use of Basaglar or GLP-1. Preferred if one is requiring to be on basal insulin and GLP-1 therapy.

SGLT-2: New starts and/or breaks in therapy for SGLT-2 therapy should consider **Steglatro/Segluromet** as it is preferred. If atherosclerotic cardiovascular disease is being managed as well, consider Jardiance/Synjardy. As of **October 1, 2019**, only **Steglatro/Segluromet** and Jardiance/Synjardy will be authorized.

DPP-4: New starts and/or breaks in therapy need to consider alogliptin. Consider **alogliptin** in place of other DDP-4's as clinically appropriate. It is the only one in the class available as a generic. Alogliptin is not recommended in members with or at risk for heart failure. Consider Tradjenta in these cases.

Syringes/pen needles: These are allowed depending on the formulation of the insulin dispensed.

Authorization submission: Please submit TARs via the Provider portal. https://provider.kernfamilyhealthcare.com Contact your company's system administrator for user access. If you are unsure who your system administrator is, please contact your Kern Health Systems Provider Relations Representative.

Sincerely,

Bruce Wearda, R.Ph. Director of Pharmacy